Skip to main content
. 2021 Jun 8;6(11):e144920. doi: 10.1172/jci.insight.144920

Figure 3. High eIF4E phosphorylation correlates with responsiveness to pharmacologic MNK1/2 inhibition in murine and human bladder cancer.

Figure 3

(A) Cell viability assay in eIF4E+/+ and eIF4ES209A/S209A bladder cancer organoids derived from BBN-treated mice (n = 3 biological replicates, P = 0.003, t test). (B) Phospho-eIF4E S209 staining across 9 bladder cancer PDX models with quantification. Scale bars: 500 μm. (C) Representative phospho-eIF4E Western blots across 3 bladder cancer organoid models treated with eFT508 (72 hours). (D) Cell viability assay of the CoCaB1, CoCaB14.1, and TM01029 PDX derived organoids treated with 0.01, 0.2, or 10 μM eFT508 for 72 hours. *P < 0.05 (CoCaB1 versus TM01029 at 0.2 μM, P = 0.03; CoCaB1 versus CoCaB14.1 at 10 μM, P = 0.03; CoCaB1 versus TM01029 at 10 μM, P = 0.04). Dunnett’s multiple-comparison test. Scale bar: 100 μm. Data are presented as mean ± SEM.